Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-FAST blood-based biomarker screening platform trial in advanced non-small cell lung cancer
MOH_2017-07-08_000608Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alectinib, atezolizumab and entrectinib in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by Roche. Started Jun 2017; status: recruiting.
02
Drugs
alectinibatezolizumabentrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-07-08_000608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-08_000608.